White Papers December 6, 2022 Lymphodepletion: systemic chemotherapy with acute toxicities and detrimental long-term consequences for anti-tumor immune function September 30, 2022 Umoja’s RACR technology drives Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs, a proprietary and uniquely scalable process for manufacturing potent and persistent engineered immune effector cells June 1, 2022 VivoVec: Our proprietary technology platform for in vivo gene delivery to T cells. September 2, 2021 The Next Step Forward in CAR T Development
